Evaluating new vaccines for developing countries: Efficacy or effectiveness?

JAMA

Volumn 275, Issue 5, 1996, Pages 390-397

  Clemens, John ^a   Brenner, Ruth ^a   Rao, Malla ^a   Tafari, Nebiat ^a   Lowe, Charles ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHOLERA VACCINE; DENGUE VACCINE; EPSTEIN BARR VIRUS VACCINE; MEASLES VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TETANUS TOXOID; TYPHOID VACCINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DENGUE; DEVELOPING COUNTRY; DRUG EFFECT; DRUG EFFICACY; EPSTEIN BARR VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; ROTAVIRUS; STATISTICAL ANALYSIS; VACCINATION; VIRUS INFECTION;

EID: 0030045041     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.5.390     Document Type: Review

References (87)

1. Robbins A, Freeman P, Powell KR. International childhood vaccine initiative. Pediatr Infect Dis. 1993;12:523-527.
2. Lee JW. Children's vaccine initiative. Science. 1994;266:527-528.
3. The World Bank. World Development Report: Investing in Health. Oxford, England: Oxford University Press; 1993.
4. Harrington D. Initial clinical evaluation of new vaccine candidates: phase I and phase II trials of safety, immunogenicity, and preliminary efficacy. In: Woodrow GC, Levine MM, eds. New Generation Vaccines. New York, NY: Marcel Dekker Inc; 1990:43-50.
5. Clemens J, Stanton B. Longer term evaluations of vaccine efficacy. In: Woodrow GC, Levine MM, eds. New Generation Vaccines. New York, NY: Marcel Dekker Inc; 1990:51-68.
6. Begg N, Miller, E. Role of epidemiology in vaccine policy. Vaccine. 1990;8:180-189.
7. Basch PF. Vaccines and World Health: Science, Policy, and Practice. New York, NY: Oxford University Press; 1994:95-122.
8. Clemens J, Sack D, Harris J, et al. Field trial of oral cholera vaccines in Bangladesh: results from long-term follow-up. Lancet. 1990;355:270-273.
9. Pierce N, Robinson D, Rigal J, Dualeh M. Cholera treatment. Lancet. 1994;344:1022.
10. Glass R, Claeson M, Blake P, et al. Cholera in Africa: lessons on transmission and control for Latin America. Lancet. 1991;338:791-795.
11. Sack D. Cholera control. Lancet. 1994;344:616-617.
12. Swerdlow D, Levine O. Cholera control among Rwandan refugees in Zaire. Lancet. 1994;344:1302-1303.
13. Blok L, Sondorp E. Cholera treatment. Lancet. 1994;344:1022-1023.
14. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunization against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338: 1055-1059.
15. Levine M, Ferreccio C, Black R, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987;1:1049-1052.
16. Ferreccio C, Levine M, Rodriguez H, et al. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis. 1989;159:766-769.
17. Levine M, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in a randomised controlled field trial. Lancet. 1990;336:891-894.
18. Acharya V, Shrestha M, Cadoz M, et al. Prevention of typhoid fever in Nepal with the Vi polysaecharide of Salmonella typhi: a preliminary report. N Engl J Med. 1987;317:1101-1104.
19. Khigman K, Gilbertson I, Korrnhof H, et al. Protective activity of Vi polysaccharide vaccine against typhoid fever. Lancet. 1987;2:1165-1169.
20. Ivanoff B, Levine M, Lambert P. Vaccination against typhoid fever: present status. Bull World Health Organ. 1994;72:957-971.
21. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzas type b polysaceharide and Neisseria meningitidis outer membrane protein complex. N Engl J Med. 1991;324:1767-1772.
22. Black S, Shinefield H, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis. 1991;10:97-104.
23. Booy R, Hodgson S, Carpenter L, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet. 1994;344:362-366.
24. Egan W, Frasch C, Anthony B. Lot-release criteria, postlicensure quality control, and the Haemophilus influenzae type b conjugate vaccines. JAMA. 1995;273:888-889.
25. Sackett DL. On some prerequisites for a successful clinical trial. In: Shapiro S, Louis T, eds. Clinical Trials: Issues and Approaches. New York, NY: Marcel Dekker Inc; 1983:65-80.
26. Schwartz D, Flamant R, Lellouch J. Clinical Trials. London, England: Academic Press; 1980.
27. Greenwood M, Yule U. The statistics of antityphoid and anti-cholera inoculations, and the interpretation of such statistics in general. Pros R Soc Med. 1915;8(pt 2):113-194.
28. Clemens J. Assessing the value of enteric vaccines: efficacy, effectiveness, and efficiency. In: Sack D, Freij L, Holmgren J, eds. Prospects for Public Health Benefits in Developing Countries From New Vaccines Against Enteric Infections. Göteborg, Sweden: SAREC Documentation; 1990:131-140. Conference report 2.
29. Donner A. Approaches to sample size estimation in the design of clinical trials - a review. Stat Med. 1984;3:199-212.
30. Fine P. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15:265-302.
31. Halloran M, Haber M, Longini I, et al. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol. 1991;133:323-331.
32. Halloran M, Struchiner C. Study designs for dependent happenings. Epidemiology. 1991;2:331-338.
33. Vesikari T, Isolauri E, D'Hondt, E, et al. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet. 1984;2:977-981.
34. Hanlon P, Hanlon L, Marsh V, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet. 1987;1:1342-1345.
35. Lanata C, Black RE, del Aguila R, et al. Protection, of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis. 1989;159:452-459.
36. De Mol P, Zissis G, Butzler J, et al. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986;2:108.
37. Wahdan M, Serie C, Derisier Y, et al A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid. J Infect Dis. 1982;145:292-295.
38. Eskola J, Kayhty H, Takala A, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzas type b disease. N Engl J Med. 1990;323:1381-1387.
39. Ward J, Brenneman G, Letson G, et al. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med. 1990;323:1393-1401.
40. Hosmer D, Lemshaw S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989:38-133.
41. Orenstein W, Bernier R, Hinman A. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev. 1988;10:212-241.
42. Orenstein W, Bernier R, Dondero T, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63:1055-1068.
43. Clemens J, Shapiro E. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis. 1984; 6:589-600.
44. Markowitz L, Katz S. Measles vaccine. In: Plotkin S, Mortimer E, eds. Vaccines. 2nd ed. Philadelphia, Pa: WB Saunders; 1994:229-276.
45. Melnick J. Live attenuated poliovirus vaccines. In: Plotkin S, Mortimer E, eds. Vaccines. 2nd ed. Philadelphia, Pa: WB Saunders; 1994:155-204.
46. Pappaioanou M, Fishbein D, Dreesen D, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med. 1986;314:280-284.
47. Pichichero ME. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. J Infect Dis. 1990;162:753-755.
48. Vadheim C, Greenberg D, Eriksen E, et al. Eradication of Haemaphilus influenzae type b disease in Southern California. Arch Pediatr Adolesc Med. 1994;48:51-56.
49. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States, 1987-93. MMWR Morb Mortal Wkly Rep 1994;43:144-146.
50. Hall A, Aaby P. Tropical trials and tribulations. Int J Epidemiol. 1990;19:777-781.
51. Aaby P, Jensen TG, Hansen H, et al. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet. 1988;2: 809-811.
52. Whittle H, Hanlon P, O'Neill K, et al. Trial of high-dose Edmonston-Zagreb measles vaccine in The Gambia: antibody response and side-effects. Lancet. 1988;2:811-814.
53. Expanded Programme on Immunization. Safety and efficacy of high titre measles vaccine at 6 months of age. Wkly Epidemiol Rec. 1991;66:269-261.
54. Garenne M, Leroy O, Beau F, Sene I. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet. 1991;338:903-920.
55. Aaby P, Samb B, Simondon F, et al. Divergent mortality for male and female recipients of low-titre and high-titre measles vaccines in rural Senegal. Am J Epidemiol. 1993;138:746-755.
56. Expanded Programme on Immunization. Safety of high titre measles vaccine. Wkly Epidemiol Rec. 1992;67:357-361.
57. Expanded Programme on Immunization. Measles immunization before 9 months of age. Wkly Epidemiol Rec. 1990;65:2-8.
58. Clemens J, Spriggs D, Sack D. Public health considerations for the use of cholera vaccines in cholera control programs. In: Wachsmuth IK, Blake P, Olsvik O, eds. Vibrio cholerae and Cholera. Washington, DC: ASM Press; 1994:425-442.
59. Clemens JD, Sack DA, van Loon FPL, et al. Non-participation as a determinant of ad verse health outcomes in a field trial of oral cholera vaccines. Am J Epidemiol. 1992;135:865-874.
60. Clemens J, Sack D, Harris J, et al. Breastfeeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol. 1990;131:400-411.
61. Clemens JD, Sack D, Harris JR, et al. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet. 1988;2:1375-1378.
62. Smith P, Rodrigues L, Fine P. Assessment of the protective efficacy of vaccines against common diseases using ease-control and cohort studies. Int J Epidemiol. 1984;13:87-93.
63. Comstock GW. Vaccination evaluation by case-control or prospective studies. Am J Epidermol. 1990;131:205-207.
64. Comstock G. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev. 1994;16:77-89.
65. Peltola H, Kilpi T, Anttila M. Rapid disappearance of H. influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet 1992;40:592-594.
66. Sackett DL, Biases in analytic research. J Chrome Dis. 1979;32:51-55.
67. Smith PG. Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method. Tubercle. 1982;62:23-35.
68. Shapiro C, Cook N, Evans D, et al. A case-control study of BCG and childhood tuberculosis in Cali, Colombia. Int J Epidemiol 1985;14:441-446.
69. Tidjani O, Amedome A, ten Dam H. The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community. Tubercle. 1986;67:269-281.
70. Padungchan S, Konjanart S, Kasiratta S, et al. The effectiveness of BCG vaccination of the newborn against childhood tuberculosis in Bangkok. Bull World Health Organ. 1986;64:247-258.
71. Stanford J, Sheikh N, Bogle G, et al. Protective effect of BCG in Ahmednagar, India. Tubercle. 1987;68:169-176.
72. Hlady WG, Bennett JV, Samadi AR, et al. Neonatal tetanus in rural Bangladesh: risk factors and toxoid efficacy. Am J Public Health. 1992;82:1365-1369.
73. Hull H, Williams P, Oldfield S. Measles mortality and vaccine efficacy in rural West Africa. Lancet. 1983;1:972-975.
74. Garenne M, Leroy O, Beau J-P, et al. Efficacy of measles vaccines after controlling for exposure. Am J Epidemiol. 1993;138:182-195.
75. McIntyre R, Preblud S, Polloi A, et al. Measles and measles vaccine efficacy in a remote island population. Bull World Health Organ. 1982;60:767-775.
76. Deming M, Jaiteh K, Otten M, et al. Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease, II: clinical efficacy of trivalent oral polio vaccine. Am J Epidemiol. 1992;135:393-408.
77. Expanded Programme on Immunization in the Americas. Polio outbreak in Honduras: clinical efficacy of trivalent oral polio vaccine tested. Expanded Programme Immunization Newslett. 1985;7:1-4.
78. Binkin N, Band J. Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy. Lancet. 1982;2:315-317.
79. Reingold A, Broome C, Hightower A, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;2:114-118.
80. Ghana Health Assessment Team. A quantitative method of assessing the health impact of different diseases in less-developed countries. Int J Epidemiol. 1981;10:73-80.
81. Drummond M. Economic evaluation and the rational diffusion and use of health technology. Health Policy. 1987;7:309-324.
82. Weinstein M, Fineberg H, Elstein A, et al. Clinical Decision Analysis. Philadelphia, Pa: WB Saunders; 1980:228-265.
83. Koenig M, Alam A, Wojtyniak B, et al. Impact of measles vaccination upon childhood mortality: results of five years of surveillance. Bull World Health Organ. 1990;68:441-447.
84. The Gambia Hepatitis Study Group. Hepatitis B vaccine in the expanded programme of immunization: the Gambian experience. Lancet. 1989;1:1057-1059.
85. Lagos R, Horwitz I, Toro J, et al. Large-scale post-licensure effectiveness and efficacy trial of PRP-T conjugate vaccine in preventing invasive Haemophilus influenzae type b infections in Chilean infants, Pediatr Infect Dis. In press.
86. Hendrickse RG. Problems of future measles vaccination in developing countries. Trans R Soc Trop Med Hyg. 1975;69:31-34.
87. Fedson DS. Policy analyses for new vaccines: their effects on the development and implementation of vaccine recommendations. In: Sack D, Freij L, eds. Prospects for Public Health Benefits in Developing Countries From New Vaccines Against Enteric Infections. Stockholm, Sweden: SAREC Documentation; 1990:131-140. Conference report 2.